Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 See also  




2 References  













Sonepiprazole






●Српски / srpski
 ●Srpskohrvatski / српскохрватски
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Sonepiprazole
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers

  • 4-(4-{2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl}piperazin-1-yl)benzenesulfonamide

CAS Number
  • as salt: 170858-34-1 checkY
    • PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
  • as salt: 980MD32QLW checkY
    • CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC21H27N3O3S
    Molar mass401.53 g·mol−1
    3D model (JSmol)

    • O=S(=O)(N)c1ccc(cc1)N2CCN(CC2)CC[C@@H]4OCCc3ccccc34

    Sonepiprazole (U-101,387, PNU-101,387-G) is a drug of the phenylpiperazine class which acts as a highly selective D4 receptor antagonist.[1] In animals, unlike D2 receptor antagonists like haloperidol, sonepiprazole does not block the behavioral effects of amphetamineorapomorphine, does not alter spontaneous locomotor activity on its own, and lacks extrapyramidal and neuroendocrine effects.[2] However, it does reverse the prepulse inhibition deficits induced by apomorphine,[3] and has also been shown to enhance cortical activity and inhibit stress-induced cognitive impairment.[4][5] As a result, it was investigated as an antipsychotic for the treatment of schizophrenia in a placebo-controlled clinical trial, but in contrast to its comparator olanzapine no benefits were found and it was not researched further for this indication.[6][7]

    See also[edit]

    References[edit]

    1. ^ TenBrink RE, Bergh CL, Duncan JN, et al. (June 1996). "(S)-(−)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist". Journal of Medicinal Chemistry. 39 (13): 2435–7. doi:10.1021/jm960084f. PMID 8691438.
  • ^ Merchant KM, Gill GS, Harris DW, et al. (December 1996). "Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist". The Journal of Pharmacology and Experimental Therapeutics. 279 (3): 1392–403. PMID 8968364.
  • ^ Mansbach RS, Brooks EW, Sanner MA, Zorn SH (January 1998). "Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition". Psychopharmacology. 135 (2): 194–200. doi:10.1007/s002130050501. PMID 9497025. S2CID 9246828.
  • ^ Rubinstein M, Cepeda C, Hurst RS, et al. (June 2001). "Dopamine D4 receptor-deficient mice display cortical hyperexcitability". Journal of Neuroscience. 21 (11): 3756–63. doi:10.1523/JNEUROSCI.21-11-03756.2001. hdl:11336/79333. PMC 6762699. PMID 11356863.
  • ^ Arnsten AF, Murphy B, Merchant K (October 2000). "The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys". Neuropsychopharmacology. 23 (4): 405–10. doi:10.1016/S0893-133X(00)00133-0. PMID 10989267.
  • ^ Unangst PC, Capiris T, Connor DT, et al. (August 1997). "Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents". Journal of Medicinal Chemistry. 40 (17): 2688–93. doi:10.1021/jm970170v. PMID 9276014.
  • ^ Corrigan MH, Gallen CC, Bonura ML, Merchant KM (March 2004). "Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial". Biological Psychiatry. 55 (5): 445–51. doi:10.1016/j.biopsych.2003.10.004. PMID 15023570. S2CID 108634.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Sonepiprazole&oldid=1135715135"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Isochromenes
     ●Phenylpiperazines
     ●Sulfonamides
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without InChI source
     ●Multiple chemicals in Infobox drug
     ●Chemicals using indexlabels
     ●Chemical articles with multiple CAS registry numbers
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 26 January 2023, at 11:27 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki